Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.

Employees

Sector

Investment Holding Companies

More about the company

Quotes

Date	Price	Change	Volume
26-07-16	CA$1.560	-12.85%	442,577
26-07-15	CA$1.790	-10.50%	168,026
26-07-14	CA$2.000	-8.68%	131,788
26-07-13	CA$2.190	-5.60%	237,231
26-07-10	CA$2.320	-1.28%	406,182

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Toronto S.E. Other stock markets 03:59:59 2026-07-16 pm EDT			5-day change	1st Jan Change
1.560 ^CAD	-12.85%		-33.62%	+3,020.00%

Jul. 15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
Jul. 08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI

Market Cap	195M 171M 158M 145M 274M 18.82B 279M 1.88B 740M 9.19B 733M 717M 31.73B	P/E 2024 *	-	P/E 2025	-0.29x
Enterprise Value	192M 168M 156M 143M 270M 18.54B 275M 1.85B 729M 9.05B 723M 707M 31.26B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	79.6%	Yield 2024 *	-	Yield 2025	-

Jul. 15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
Jul. 08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
Jul. 07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
Jun. 30	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI
Jun. 12	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform	CI
Jun. 08	Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors	CI
May. 13	Vector Science and Therapeutics enters option to buy up to 15% of Lyogenesis Plus for up to $1 million	RE
May. 11	Vector Science & Therapeutics Inc. Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC	CI
May. 11	Vector Science & Therapeutics enters three-year development and manufacturing agreement with MPP Group LLC	RE
May. 06	Vector Science & Therapeutics Corp. Announces Appointment of Dr. Alexander Dobranowski and Scott Kelly to Board of Directors	CI
May. 04	Vector Science and Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026	CI

Jul. 15	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ
Jul. 07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio	AQ
Jun. 30	Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform	AQ
Jun. 22	Gary Payton II Named Chief Athletic Ambassador of Valor	AQ
Jun. 15	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform	AQ

Vector Science and Therapeutics Corp. Stock

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Valuation: Vector Science and Therapeutics Corp.

Chart: Vector Science and Therapeutics Corp.

Latest news : Vector Science and Therapeutics Corp.

Press Releases: Vector Science and Therapeutics Corp.

Quotes and Performance

Course Extremes

Latest insider transactions

Shell Companies

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-12.85%
1 week	-33.62%
Current month	-36.33%
1 month	-28.44%
3 months	+321.62%
6 months	+321.62%
Current year	+3,020.00%

1 week	1.5	2.35
1 month	1.5	2.65
Current year	0.35	2.65
1 year	0.35	2.65
3 years	0.03	2.65
5 years	0.03	2.65
10 years	0.03	2.65

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/29/26	Tommy Thompson	Option	Chairman	68,870	0.0741%
5/29/26	Alexander Dobranowski	Option	Director	68,870	0.0741%
5/29/26	Scott Kelly	Option	Director	68,870	0.0741%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VECTOR SCIENCE AND THERAPEUTICS CORP.	-12.85%	-33.62%	+321.62%	+2,500.00%	195M
CHURCHILL CAPITAL CORP XI	-7.18%	-9.98%	-	-	877M
EINRIDE AB	-7.65%	-28.98%	-	-	762M
PRIME BEING CORP.	0.00%	0.00%	+44.74%	+391.07%	797M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	642M
DEEP FISSION, INC.	-13.57%	-5.66%	-	-	734M
CHURCHILL CAPITAL CORP XII	-0.19%	-0.37%	-	-	611M
CANTOR EQUITY PARTNERS IV, INC.	+0.08%	+0.29%	-	-	597M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.20%	0.00%	-	-	596M
Average	-4.56%	-4.95%	+183.18%	+1,445.54%	645.58M
Weighted average by Cap.	-4.21%	-3.53%	+99.24%	+806.18%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-